Skip to main content
. Author manuscript; available in PMC: 2014 Nov 5.
Published in final edited form as: Circulation. 2011 Jul 18;124(6):695–703. doi: 10.1161/CIRCULATIONAHA.110.014860

Table 3.

Estimates of Effects of Drugs Used in IS and IP Treatment Strategy on Repeated Measures of Analytes*

IP Drugs
 IS Drugs
Analyte Insulin P Sulfonylurea P Thiazolidinedione P Biguanide P
tPA, ng/mL 0.37 <0.0001 0.24 <0.0001 –1.57 <0.0001 –0.83 <0.0001
log(PAI-1 antigen) 0.031 0.011 0.078 <0.0001 –0.16 <0.0001 –0.070 <0.0001
log(PAI-1 activity) 0.029 0.060 0.11 <0.0001 –0.16 <0.0001 –0.062 <0.0001
log(CRP) 0.17 0.0011 0.022 0.64 –0.33 <0.0001 –0.17 0.0033
log(FPA) 0.062 0.27 –0.061 0.25 –0.09 0.15 –0.12 0.07
log(D-dimer) 0.031 0.44 –0.024 0.52 0.004 0.93 –0.21 <0.0001
Fibrinogen, mg/dL 16.6 <0.0001 9.33 0.019 –5.02 0.30 –13.4 0.006

IP indicates insulin-providing; IS, insulin-sensitizing; tPA, tissue plasminogen activator; PAI-1, plasminogen activator inhibitor type 1; CRP, C-reactive protein; and FPA, fibrinopeptide A. The P value indicates the significance level of the estimated drug effect on the analyte.

*

Analysis also includes indicators for follow-up period of analyte measure, IP/IS randomization, age, gender, race/ethnicity, baseline body mass index, duration of diabetes mellitus, and concurrent hemoglobin A1c.